Biopharma · FDA Approvals · Stock

LSTA Caladrius Biosciences

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tet…

Assets on file: MAR001

Start live analysis of LSTA Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for LSTA, including recently decided ones.

November 2027

Nov 2027

~ Nov 2027

LSTACaladrius Biosciences

MAR001: Phase 2 trial NCT07028749 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Recent first-hand events

Every first-hand event for LSTA, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Sep 17, 2026

01:27 PM

LSTACaladrius Biosciences

Lisata Therapeutics Acquires Marea Therapeutics, Raises $225M

Lisata acquired Marea in a stock-for-stock deal and raised $225M in a concurrent private placement to advance MAR001/005 (Phase 2b in sHTG) and MAR002 (Phase 2 in acromegaly). Topline data from both ongoing Phase 2 studies is guided for Q4 2027, followed by planned initiation of Phase 3 registrational studies. The combined entity will focus on cardioendocrine diseases while also evaluating next steps for Lisata's certepetide.

Partnership / licensing dealSEC 8-K Open record